{
    "nct_id": "NCT04252287",
    "official_title": "Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure",
    "inclusion_criteria": "- Have clinically stable symptomatic heart failure (HF) (heart failure with reduced ejection fraction [HFrEF] and heart failure with preserved ejection fraction [HFpEF]): (A) For HFrEF: (a) ejection fraction (EF) less than or equal to (<=) 40 percent (%) and (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months (B) For HFpEF: (a) EF greater than (>) 40%; (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months, AND; (C) on a loop diuretic or spironolactone or eplerenone (mineralocorticoid receptor antagonists), in the past 18 months\n\n* Have a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) score of less than or equal to (<=) 80 prior to randomization\n* Be able to read and understand English\n* Possess and have sole use (example: not shared with other users) of smartphone compatible with the Fitbit device\n* Willing/able to wear the Fitbit device on a regular basis for the 9-month study period\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently taking a sodium-glucose co-transporter 2 inhibitor (SGLT2i) or within the last 3 months\n* History of diabetic ketoacidosis or have type 1 diabetes mellitus (T1DM)\n* Have acute decompensated HF (exacerbation of symptomatic HF) requiring intravenous diuretics, inotropes, or vasodilators within the last 4 weeks\n* Have stage 4 or 5 Chronic Kidney Disease (that is, estimated glomerular filtration rate [eGFR] <30 milliliter per minute [ml/min] on dialysis) from the most recent assessment\n* Have a diagnosis of hypotension within 30 days",
    "miscellaneous_criteria": ""
}